How semaglutide reduces weight: what's actually happening in your body

What GLP-1 does, and why semaglutide amplifies it so effectively

When you finish a meal, your gut releases a hormone called glucagon-like peptide-1 (GLP-1). It tells the brain you've had enough, nudges the pancreas to release insulin in proportion to how much glucose arrived, and slows the passage of food from the stomach into the small intestine. All of this dampens hunger and prevents blood sugar from spiking sharply. The catch is that the body breaks down natural GLP-1 within minutes.

Semaglutide is a synthetic molecule designed to survive that breakdown. It binds to the same GLP-1 receptor but stays active for around seven days, which is why a single weekly injection sustains the effect. The practical consequence is a persistent reduction in appetite that most people notice within days of starting treatment, and a meaningful shift in how much they want to eat at any given meal. Whether that translates to reduced cravings specifically is a question many patients bring to their first consultation, the short answer is that the research supports it.

This mechanism is well-documented in NHS guidance on semaglutide, which describes both the appetite and gastric-emptying pathways. It is also the reason the medicine's effects are tied to the dose: higher doses bind more receptors, producing a stronger signal, which is why treatment is titrated gradually rather than started at full strength.

How the brain and gut work together to produce the calorie deficit

Weight loss ultimately comes down to a sustained calorie deficit, consuming less energy than the body uses. Semaglutide creates that deficit through two routes acting at the same time, rather than relying on willpower alone to override hunger.

In the brain, semaglutide acts on the hypothalamus, the region responsible for hunger regulation. Appetite signals are turned down; the reward signal from highly palatable foods is also blunted for many people. In the gut, slowed gastric emptying means food stays in the stomach longer, so the physical sensation of fullness persists well past the point it would without the medicine. Between the two, patients typically eat less at each meal and feel less urgency to snack between meals.

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight plus at least one weight-related condition over 68 weeks. Those receiving 2.4mg semaglutide weekly lost an average of around 15% of body weight, compared with about 2.4% in the placebo group. That gap reflects the sustained calorie deficit the mechanism creates over time.

One thing worth knowing: the weight loss is not uniform across the body. How semaglutide affects visceral fat specifically is an area patients frequently ask about, and the evidence there is meaningful for long-term metabolic health.

What this means if you're deciding whether semaglutide is the right approach for you

Understanding the mechanism helps frame the decision clearly. Semaglutide is not a short-term appetite suppressant; it is a medicine that resets the hormonal signalling around hunger for as long as treatment continues. That has real implications for who benefits, what to expect at different stages, and what happens if treatment stops.

The licensed version for weight management in the UK is Wegovy, available in a once-weekly pre-filled injection pen, with the MHRA having also approved a higher 7.2mg dose pen in April 2026 for adults with a BMI of 30 or above. Treatment starts at 0.25mg and is titrated upward by the prescriber over several months. The titration schedule exists because the gastric-emptying effect, helpful for weight loss, also accounts for the nausea and digestive discomfort that can occur when the dose rises too quickly. Keeping the pen in the fridge door and injecting on the same day each week are the kinds of small routines that make the schedule easier to stick to.

There is also a meaningful question about how semaglutide affects lean tissue. The evidence on muscle mass during treatment is worth reading before you start, particularly if you are physically active. And because semaglutide also influences glucose regulation, its effect on blood sugar is relevant for anyone at the prediabetic range.

For a fuller picture of the medicine itself, our Wegovy overview covers eligibility, the full dosing pathway, and what to expect from treatment in practice. If you want to explore costs before committing to a consultation, the Wegovy price page sets out what private treatment typically involves and what a transparent service price includes.

When a clinical assessment makes the difference

Knowing how semaglutide works is genuinely useful. Knowing whether it is suitable for you requires a prescriber who can see the whole picture: your health history, any medicines you take, your BMI and any weight-related conditions, and how your lifestyle fits with a weekly injection. Our semaglutide information page goes into more detail on UK licensing and who the medicine is intended for under NICE guidance.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it is submitted, a real clinician, not a screening algorithm. Our clinical team's approach is outlined on the clinical team profile. If you have questions before you start, the FAQs cover the most common ones.

If semaglutide sounds like it could be the right fit, the next step is a free consultation. Start your free consultation and our prescribers will assess your suitability the same day.